uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Latest Posted July 22, 2024

Umary Hyaluronic Acid Supplement Recalled

On July 15, 2024, issued a recall of all lots of Umary Acido Hialuronica, Suplemento Alimenticio (“Umary Hyaluronic Acid, Food Supplement”) capsules after FDA testing found them to contain diclofenac and omeprazole, drugs that are not permitted to be sold as supplements.

(See ConsumerLab’s Review of Joint Health Supplements for more information about hyaluronic acid and tests of related supplements.)

Diclofenac is an anti-inflammatory drug (also known as NSAIDs) and consumption of high levels could result in serious adverse events. Cardiovascular, gastrointestinal, renal, and anaphylaxis issues may occur for those taking NSAIDs and/ or anticoagulants. This includes consumers with underlying cardiovascular, gastrointestinal, renal and hepatic illness.

Omeprazole is a proton pump inhibitor (also known as PPI) and is used for stomach acid disorders. PPI medications may cause skin reactions, abdominal pain, diarrhea, nausea, and headache. Omeprazole should not be taken with certain medications as it may hide potential stomach issues including erosions, ulcers, or stomach cancer.

Umary Hyaluronic Acid (see product photos) is packaged in bottles with 30 850-mg capsules and were sold online nationwide. Consumers who have this product are advised to stop use immediately.

Umary Hyaluronic Acid was previously recalled in Canada, in May 2024, after a consumer reported experiencing an adverse reaction to the supplement and testing by Health Canada (the Canadian equivalent of the U.S. FDA) revealed the presence of diclofenac and omeprazole in the supplement.

The company is notifying consumers via email, arranging for the return of the products.

Consumers should contact their healthcare provider if they have experienced any problems related to taking these drug products. Consumers and or healthcare providers are advised to report any adverse reactions to the FDA’s MedWatch Voluntary Reporting Program by fax, mail, or online.

Also see ConsumerLab’s article about supplements promoted to help with arthritis

For more information, use the link below. Issues Voluntary Nationwide Recall of Umary Acido Hialuronica, Suplemento Alimenticio 850 mg Capsules Due to the Presence of Undeclared Drug Ingredients: Diclofenac and Omeprazole

See related recalls and warnings:

Drug Found in Umary Supplement

Pain Relief Tea Recalled, Found to Contain Prescription Drugs

Joint Pain Supplements Recalled Due to Undeclared Drug Ingredients

FDA Warns Consumers Not to Use Tapee Tea

Toxic Herb Found In Weight Supplements